Primary hypertension is a disease of premature vascular aging associated with neuro-immuno-metabolic abnormalities

Pediatric Nephrology

Volumn 31, Issue 2, 2016, Pages 185-194

  Litwin, Mieczysław ^a   Feber, Janusz ^b   Niemirska, Anna ^a   Michałkiewicz, Jacek ^a,c  

^a CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

^b CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^c NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

Children; Immunologic activity; Metabolic syndrome; Primary hypertension; Sympathetic activity; Target organ damage; Vascular aging

Indexed keywords

ADAPTIVE IMMUNITY; ADOLESCENT DISEASE; ADRENERGIC SYSTEM; AUTONOMIC NERVOUS SYSTEM; BODY MASS; CARDIORESPIRATORY FITNESS; CARDIOVASCULAR RISK; CHILDHOOD DISEASE; GLUCOSE TRANSPORT; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; INSULIN RESISTANCE; OBESITY; PATHOGENESIS; PHENOTYPE; PREVALENCE; PRIMARY HYPERTENSION; PRIORITY JOURNAL; REJUVENATION; REVIEW; WAIST CIRCUMFERENCE; BODY COMPOSITION; CHILD; COMPLICATION; HEMODYNAMICS; IMMUNOLOGY; METABOLIC SYNDROME X; PATHOPHYSIOLOGY; PREMATURE AGING;

AGING, PREMATURE; BODY COMPOSITION; CHILD; HEMODYNAMICS; HUMANS; HYPERTENSION; METABOLIC SYNDROME X; OBESITY; SYMPATHETIC NERVOUS SYSTEM;

EID: 84952876734     PISSN: 0931041X     EISSN: 1432198X     Source Type: Journal    
DOI: 10.1007/s00467-015-3065-y     Document Type: Review

References (102)

1. Page IH (1949) Pathogenesis of arterial hypertension. J Am Med Assoc 140:451–458
2. Harrison DG (2013) The mosaic theory revisited: common molecular mechanisms coordinating diverse organ and cellular events in hypertension. J Am Soc Hypertens 7:68–74
3. Paradis G, Lambert M, O’Loughlin J, Lavallée C, Aubin J, Delvin E, Lévy E, Hanley JA (2004) Blood pressure and adiposity in children and adolescents. Circulation 110:1832–1838
4. Sorof J, Daniels S (2002) Obesity hypertension in children: a problem of epidemic proportions. Hypertension 40:441–447
5. Flynn JT, Alderman MH (2005) Characteristics of children with primary hypertension seen at a referral centre. Pediatr Nephrol 20:961–966
6. Litwin M, Trelewicz J, Wawer Z, Antoniewicz J, Wierzbicka A, Rajszys P, Grenda R (2004) Intima-media thickness and arterial elasticity in hypertensive children: controlled study. Pediatr Nephrol 19:767–774
7. Srinivasan SR, Myers L, Berenson GS (2006) Changes in metabolic syndrome variables since childhood in pre-hypertensive and hypertensive subjects: the Bogalusa Heart Study. Hypertension 48:33–39
8. Sinaiko A, Steinberger J, Moran A, Hong C, Prineas R, Jacobs D (2006) Influence of insulin resistance and body mass index at Age 13 on systolic blood pressure, triglycerides, and high-density lipoprotein cholesterol at Age 19. Hypertension 48:730–736
9. Pludowski P, Litwin M, Sladowska J, Antoniewicz J, Niemirska A, Wierzbicka A, Lorenc RS (2008) Bone mass and body composition in children and adolescents with primary hypertension: preliminary data. Hypertension 51:77–83
10. Litwin M, Sladowska J, Antoniewicz J, Niemirska A, Wierzbicka A, Daszkowska J, Wawer ZT, Janas R, Grenda R (2007) Metabolic abnormalities, insulin resistance, and metabolic syndrome in children with primary hypertension. Am J Hypertens 20:875–882
11. Feig DI, Johnson RJ (2003) Hyperuricemia in childhood primary hypertension. Hypertension 42:247–252
12. Feig DI, Johnson RJ (2007) The role of uric acid in pediatric hypertension. J Ren Nutr 17:79–83
13. Feig DI, Soletsky B, Johnson RJ (2008) Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 300:924–932
14. Redón J, Oliva MR, Tormos C, Giner V, Chaves J, Iradi A, Sáez GT (2003) Antioxidant activities and oxidative stress byproducts in human hypertension. Hypertension 41:1096–1101
15. Goonasekera CD, Rees DD, Woolard P, Frend A, Shah V, Dillon MJ (1997) Nitric oxide synthase inhibitors and hypertension in children and adolescents. J Hypertens 15:901–909
16. Ostrow V, Wu S, Aguilar A, Bonner R Jr, Suarez E, De Luca F (2011) Association between oxidative stress and masked hypertension in a multi-ethnic population of obese children and adolescents. J Pediatr 158:628–633
17. Túri S, Friedman A, Bereczki C, Papp F, Kovàcs J, Karg E, Németh I (2003) Oxidative stress in juvenile essential hypertension. J Hypertens 21:145–152
18. Sladowska-Kozłowska J, Litwin M, Niemirska A, Płudowski P, Wierzbicka A, Skorupa E, Wawer ZT, Janas R (2012) Oxidative stress in hypertensive children before and after 1 year of antihypertensive therapy. Pediatr Nephrol 27:1943–1951
19. Litwin M, Niemirska Ś-KJ, Wierzbicka A, Janas R, Wawer ZT, Wisniewski A, Feber J (2010) Regression of target organ damage in children and adolescents with primary hypertension. Pediatr Nephrol 25:2489–2499
20. Lever AF, Harrap SB (1992) Essential hypertension: a disorder of growth with origins in childhood? J Hypertens 10:101–120
21. Katz SH, Hediger ML, Schall JI, Bowers IJ, Barker WF, Aurand S, Eveleth PB, Gruskin AB, Parks JS (1980) Blood pressure, growth and maturation from childhood through adolescence: mixed longitudinal analyses from Philadelphia Blood Pressure Project. Hypertension 2:55–69
22. Cho SD, Mueller W, Meininger JC, Liehr P, Chan W (2001) Blood pressure and sexual maturity In adolescents: the Heartfelt Study. Am J Hum Biol 13:227–234
23. Pludowski P, Litwin M, Niemirska A, Jaworski M, Sladowska J, Kryskiewicz E, Karczmarewicz E, Neuhoff-Murawska J, Wierzbicka A, Lorenc RS (2009) Accelerated skeletal maturation in children with primary hypertension. Hypertension 54:1234–1239
24. Sun SS, Schubert CM (2009) Prolonged juvenile states and delay of cardiovascular and metabolic risk factors: The Fels Longitudinal Study. J Pediatr 155(suppl 7):e1–e6
25. Halldorsson T, Gunnarsdottir I, Birgisdottir BE, Gudnason V, Aspelund T, Thorsdottir I (2010) Childhood growth and adult hypertension in a population of high birth weight. Hypertension 58:8–15
26. Kivimaki M (2008) Association of age at menarche with cardiovascular risk factors, vascular structure, and function in adulthood: The Cardiovascular Risk in Young Finns Study. Am J Clin Nutr 87:1876–1882
27. Okuda T, Grollman (1967) Passive transfer of autoimmune induced hypertension in the rat by lymph node cells. Tex Rep Biol Med 25:257–264
28. Svendsen UG (1975) Studies elucidating the importance of thymus on the degree of increased blood pressure and vascular disease in renal hypertensive mice. A comparison of the disease in nude and haired littermates. Acta Pathol Microbiol Scand A 83:568–572
29. Svendsen UG (1976) The role of thymus for the development and prognosis of hypertension and hypertensive vascular disease in mice following renal infarction. Acta Pathol Microbiol Scand A 84:235–243
30. Svendsen UG (1977) Spontaneous hypertension and hypertensive vascular disease in the NZB strain of mice. Acta Pathol Microbiol Scand A 85:548–554
31. Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, Goronzy J, Weyand C, Harrison DG (2007) Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med 204:2449–2460
32. Barhoumi T, Kasal DA, Li MW, Shbat L, Laurant P, Neves MF, Paradis P, Schiffrin EL (2011) T regulatory lymphocytes prevent angiotensin II-induced hypertension and vascular injury. Hypertension 57:469–476
33. Chae CU, Lee RT, Rifai N, Ridker PM (2001) Blood pressure and inflammation in apparently healthy man. Hypertension 38:399–403
34. Festa A, Jr A, Howard G, Mykkänen L, Tracy RP, Haffner SM (2000) Chronic subclinical inflammation as a part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102:42–47
35. Lande MB, Pearson TA, Vermilion RP, Auinger P, Fernandez ID (2008) Elevated blood pressure, race/ethnicity, and C-reactive protein levels in children and adolescents. Pediatrics 122:1252–1257
36. Litwin M, Michalkiewicz J, Niemirska A, Gackowska L, Kubiszewska I, Wierzbicka A, Wawer ZT, Janas R (2010) Inflammatory activation in children with primary hypertension. Pediatr Nephrol 25:2489–2499
37. Jurewicz M, McDermott DH, Sechler JM, Tinckam K, Takakura A, Carpenter CB, Milford E, Abdi R (2007) Human T and natural killer cells possess a functional renin–angiotensin system: further mechanisms of angiotensin-induced inflammation. J Am Soc Nephrol 18:1093–1102
38. Hoch NE, Guzik TJ, Chen W, Deans T, Maalouf SA, Gratze P, Weyand C, Harrison DG (2009) Regulation of T cell function by endogenously produced angiotensin II. Am J Physiol Regul Integr Comp Physiol 296:208–216
39. Benicky J, Sanchez-Lemus E, Pavel J, Saavedra JM (2009) Anti-inflammatory effects of angiotensin receptor blockers in the brain and the periphery. Cell Moll Neurobiol 29:781–792
40. Chon H, Gaillard CAJM, van der Meijden BB, Dijstelbloem HM, Kraaijenhagen RJ, van Leenen D, Holstege FC, Joles JA, Bluyssen HA, Koomans HA, Braam B (2004) Broadly altered gene expression in blood leukocytes in essential hypertension is absent during treatment. Hypertension 43:947–951
41. Coppo M, Bandinelli M, Berni A, Galastri S, Abbate R, Poggesi L, Marra F, Gensini GF, Boddi M (2011) Ang-II upregulation of T lymphocyte renin–angiotensin system is amplified by low-grade inflammation in human hypertension. Am J Hypertens 24:716–723
42. Litwin M, Michałkiewicz TJ, Niemirska A, Wierzbicka A, Szalecki M (2013) Altered genes profile of renin–angiotensin system, immune system, and adipokines receptors in leukocytes of children with primary hypertension. Hypertension 61:431–436
43. Bierhaus A, Humpert PM, Nawroth PP (2004) NF-kappaB as a molecular link between psychosocial stress and organ dysfunction. Pediatr Nephrol 19:1189–1191
44. Bierhaus A, Wolf J, Andrassy M, Rohleder N, Humpert PM, Petrov D, Ferstl R, von Eynatten M, Wendt T, Rudofsky G, Joswig M, Morcos M, Schwaninger M, McEwen B, Kirschbaum C, Nawroth PP (2003) A mechanism converting psychosocial stress into mononuclear cell activation. Proc Natl Acad Sci U S A 100:1920–1925
45. Youn J-C, Yu HT, Lim BJ, Koh MJ, Lee J, Chang D-Y, Choi YS, Lee S-H, Kang S-M, Jang Y, Yoo OJ, Shin E-C, Park S (2013) Immunosenescent CD8+ T cells and C-X-C chemokine receptor type 3 chemokines are increased in human hypertension. Hypertension 62:126–133
46. Feber J, Ruzicka M, Geier P, Litwin M (2014) Autonomic nervous system dysregulation in pediatric hypertension. Curr Hypertens Rep 16:426
47. Niemirska A, Obrycki Ł, Wojciechowska E, Litwin M (2014) Hemodynamics of primary hypertension in children. Pediatr Nephrol 29:1724 (abstract)
48. Julius S, Valentini M, Palatini P (2000) Overweight and Hypertension: a two-way street? Hypertension 35:807–813
49. Greenfield JR, Miller JW, Keogh JM, Henning E, Satterwhite JH, Cameron GS, Astruc B, Mayer JP, Brage S, See TC, Lomas DJ, O’Rahilly S, Farooqi IS (2009) Modulation of blood pressure by central melanocortinergic pathways. N Engl J Med 360:44–52
50. Syme C, Abrahamowicz M, Leonard GT, Perron M, Pitiot A, Qiu X, Richer L, Totman J, Veillette S, Xiao Y, Gaudet D, Paus T, Pausova Z (2008) Intra-abdominal adiposity and individual components of the metabolic syndrome in adolescence: sex differences and underlying mechanisms. Arch Pediatr Adolesc Med 162:453–461
51. Kułaga Z, Litwin M, Grajda A, Kułaga K, Gurzkowska B, Góźdź M, Pan H; OLAF Study Group (2012) Oscillometric blood pressure percentiles for Polish normal weight school-aged children and adolescents. J Hypertens 30:1942–1954
52. Litwin M, Simonetti GD, Niemirska A, Ruzicka M, Wühl E, Schaefer F, Feber J (2010) Altered cardiovascular rhythmicity in children with white coat and ambulatory hypertension. Pediatr Res 67:419–423
53. Niemirska A, Litwin M, Feber J, Jurkiewicz E (2013) Blood pressure rhythmicity and visceral Fat in children with hypertension. Hypertension 62:782–788
54. Stabouli S, Kotsis V, Rizos Z, Toumanidis S, Karagianni C, Constantopoulos A, Zakopoulos N (2009) Left ventricular mass in normotensive, pre-hypertensive and hypertensive children and adolescents. Pediatr Nephrol 24:1545–1551
55. Kollias A, Dafni M, Poulidakis E, Ntineri A, Stergiou GS (2014) Out of office blood pressure and target organ damage in children and adolescents: a systematic review and meta-analysis. J Hypertens 32:2315–2331
56. Litwin M, Niemirska A, Ruzicka M, Feber J (2009) White coat hypertension in children: not rare and not benign? J Am Soc Hypertens 3:416–423
57. Sorof JM, Cardwell G, Franco K, Portman RJ (2002) Ambulatory blood pressure and left ventricular mass in hypertensive children. Hypertension 39:903–908
58. Ltwin M, Niemirska A, Sladowska J, Antoniewicz J, Daszkowska J, Wierzbicka A, Wawer ZT, Grenda R (2006) Left ventricular hypertrophy and arterial wall thickening in children with essential hypertension. Pediatr Nephrol 21:811–819
59. Brady TM, Fivush B, Flynn JT, Parekh R (2008) Ability of blood pressure to predict left ventricular hypertrophy in children with primary hypertension. J Pediatr 152:73–78
60. Gerhard-Herman M, Smoot LB, Wake N, Kieran MW, Kleinman ME, Miller DT, Schwartzman A, Giobbie-Hurder A, Neuberg D, Gordon LB (2012) Mechanisms of premature vascular aging in children with Hutchinson–Gilford progeria syndrome. Hypertension 59:92–97
61. Kotsis V, Stabouli S, Karafillis I, Nilsson P (2011) Early vascular aging and the role of central blood pressure. J Hypertens 29:1847–1853
62. Ferreira I, van de Laar RJ, Prins MH, Twisk JW, Stehouwer CD (2012) Carotid stiffness in young adults: a life-course analysis of its early determinants: the Amsterdam Growth and Health Study. Hypertension 59:54–61
63. Harrison DG1, Guzik TJ, Lob HE, Madhur MS, Marvar PJ, Thabet SR, Vinh A, Weyand CM (2011) Inflammation, immunity, and hypertension. Hypertension 57:132–140
64. Rodríguez-Iturbe B, Pons H, Quiroz Y, Johnson RJ (2014) The immunological basis of hypertension. Am J Hypertens 27:1327–1337
65. Rodriguez-Iturbe B, Vaziri ND, Herrera-Acosta J, Johnson RJ (2004) Oxidative Stress, Renal infiltration of immune cells and salt-sensitive hypertension: all for one and one for all. Am J Physiol Renal Physiol 286:606–616
66. Parra G, Quiroz Y, Salazar J, Bravo Y, Pons H, Chavez M, Rj J, Rodriguez-Iturbe B (2008) Experimental induction of salt-sensitive hypertension is associated with lymphocyte proliferative response to HSP70. Kidney Int 74:S55–S59
67. Pons H, Ferrebuz A, Quiroz Y, Romero-Vasquez F, Parra G, Johnson RJ, Rodriguez-Iturbe B (2013) Immune reactivity to heat shock protein 70 expressed in the kidney is cause of salt sensitive hypertension. Am J Physiol Renal Physiol 304:289–299
68. Frostegard J, Lemne C, Andersson B, van der Zee R, Kiessling R, deFaire U (1997) Association of serum antibodies to heat-shock protein 65 with borderline hypertension. Hypertension 29:40–44
69. Pockley AG, Wu R, Lemne C, Kiessling R, de Faire U, Frostegard J (2000) Circulating heat shock protein 60 is associated with early cardiovascular Disease. Hypertension 36:303–307
70. Knoflach M, Bernhard D, Wick G (2005) Anti-HSP60 immunity is already associated with atherosclerosis early in life. Ann N Y Acad Sci 1051:323–331
71. Knoflach M, Kiechl S, Mayrl B, Kind M, Gaston JS, van der Zee R, Faggionato A, Mayr A, Willeit J, Wick G (2007) T-cell reactivity against HSP60 relates to early but not advanced atherosclerosis. Atherosclerosis 195:333–338
72. Bravo Y, Quiroz Y, Ferrebuz A, Vaziri ND, Rodríguez-Iturbe B (2007) Mycophenolate mofetil administration reduces renal inflammation, oxidative stress, and arterial pressure in rats with lead-induced hypertension. Am J Physiol Renal Physiol 293:616–623
73. Herrera J, Ferrebuz A, MacGregor EG, Rodriguez-Iturbe B (2006) Mycophenolate mofetil treatment improves hypertension in patients with psoriasis and rheumatoid arthritis. J Am Soc Nephrol 17:218–225
74. Baradaran A, Nasri H, Rafieian-Kopaei M (2014) Oxidative stress and hypertension: Possibility of hypertension therapy with antioxidants. J Res Med 19:358–367
75. Roque FR, Hernanz R, Salaices M, Briones AM (2013) Exercise training and cardiometabolic diseases: focus on the vascular system. Curr Hypertens Rep 15:204–214
76. Kokkinos P (2014) Cardiorespiratory fitness, exercise, and blood pressure. Hypertension 64:1160–1164
77. Liu J, Sui X, Lavie CJ, Zhou H, Park YM, Cai B, Liu J, Blair SN (2014) Effects of cardiorespiratory fitness on blood pressure trajectory with aging in a cohort of healthy men. J Am Coll Cardiol 64:1245–1253
78. Leary SD, Ness AR, Smith GD, Cs M, Deere K, Blair SN, Riddoch C (2008) Physical activity and blood pressure in childhood: findings from a population based study. Hypertension 82:16–23
79. Rocchini AP, Katch V, Anderson J, Hinderliter J, Becque J, Martin M, Marks C (1988) Blood pressure in obese adolescents: effect of weight loss. Pediatrics 82:16–23
80. Woo KS, Chook P, Yu CW, Sung RY, Qiao M, Leung SS, Lam CW, Metreweli C, Celermajer DS (2004) Effects of diet and exercise on obesity-related vascular dysfunction in children. Circulation 109:1981–1986
81. Messerli FH, Bangalore S, Julius S (2008) Risk/benefit assessment of beta-blockers and diuretics precludes their use for first-line therapy in hypertension. Circulation 117:2706–2715
82. Elliott WJ, Meyer PM (2007) Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 369:201–207
83. Barzilay JI, Davis BR, Cutler JA, Pressel SL, Whelton PK, Basile J, Margolis KL, Ong ST, Sadler LS, Summerson J; ALLHAT Collaborative Research Group (2006) Fasting glucose levels and incident diabetes mellitus in older non-diabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 166:2191–2201
84. Rizos CV, Elisaf MS (2014) Antihypertensive drugs and glucose metabolism. World J Cardiol 6:517–530
85. Sharma AM, Pischon T, Hardt S, Kunz I, Luft FC (2001) Hypothesis: Beta-adrenergic receptor blockers and weight gain: a systematic analysis. Hypertension 37:250–254
86. Bangalore S, Parkar S, Grossman E, Messerli FH (2007) A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol 100:1254–1262
87. Falkner B, Francos G, Kushner H (2006) Metoprolol succinate, a selective b-adrenergic blocker, has no effect on insulin sensitivity. J Clin Hypertens (Greenwich) 8:336–343
88. Falkner B, Kushner H (2008) Treatment with metoprolol succinate, a selective beta adrenergic blocker, lowers blood pressure without altering insulin sensitivity in diabetic patients. J Clin Hypertens (Greenwich) 10:51–57
89. Agabiti Rosei E, Rizzoni D (2007) Metabolic profile of nebivolol, a beta-adrenoceptor antagonist with unique characteristics. Drugs 67:1097–1107
90. Ayers K, Byrne LM, DeMatteo A, Brown NJ (2012) Differential effects of nebivolol and metoprolol on insulin sensitivity and plasminogen activator inhibitor in the metabolic syndrome. Hypertension 59:893–898
91. Noto H, Goto A, Tsjimoto T, Noda M (2013) Effect of calcium channel blockers on incidence of diabetes: a meta-analysis. Diabetes Metab Syndr Obes 6:257–261
92. Shen L, Shah BR, Reyes EM, Thomas L, Wojdyla D, Diem P, Leiter LA, Charbonnel B, Mareev V, Horton ES, Haffner SM, Soska V, Holman R, Bethel MA, Schaper F, Sun JL, McMurray JJ, Califf RM, Krum H (2013) Role of diuretics, β blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study. BMJ 347:f6745
93. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342:145–153
94. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, LIFE Study Group (2002) Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 359:995–1003
95. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmäki K, Dahlöf B, de Faire U, Mörlin C, Karlberg BE, Wester PO, Björck JE (1999) Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomized trial. Lancet 353:611–616
96. Abuissa H, Jones PG, Marso SP, O’Keefe JH (2005) Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 46:821–826
97. Engeli S, Böhnke J, Gorzelniak K, Janke J, Schling P, Bader M, Luft FC, Sharma AM (2005) Weight loss and the renin-angiotensin-aldosterone system. Hypertension 45:356–362
98. Dharma AM (2002) Adipose tissue: a mediator of cardiovascular risk. Int J Obes Relat Metab Disord 4:5–7
99. Gorzelniak K, Engeli S, Janke J, Luft FC, Sharma AM (2002) Hormonal regulation of the human adipose-tissue renin–angiotensin system: relationship to obesity and hypertension. J Hypertens 20:965–973
100. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW (2004) Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 43:993–1002
101. Shimabukuro M, Tanaka H, Shimabukuro T (2007) Effects of telmisartan on fat distribution in individuals with the metabolic syndrome. J Hypertens 25:841–848
102. Michalkiewicz J, Barth C, Chrzanowska K, Gregorek H, Syczewska M, Weemeas CMB, Madaliński K, Dzierżanowska D, Stachowski J (2003) Abnormalities in the T and NK lymphocyte phenotype in patients with Nijmegen breakage syndrome. Clin Exp Immunol 134:482–490